PharmaCielo Receives Approval For US$3 Million Import Contract

PharmaCielo Ltd (TSXV: PCLO) has become one of the first venture listed equities to receive approval for the importation of cannabidiol isolate to the United States. The company announced this morning that the exchange has finally granted the approval, which will allow the company to fulfill its previously announced supply agreement.

The supply agreement, announced in late September 2019, was anticipated to be fulfilled by the end of the year as per the original text of the release. This was delayed however as a result of requiring exchange approval for the transaction. The contract stipulates that medicinal grade CBD isolate was to be provided to General Extract, LLC.

In total, the contract itself is for US$3 million, which marks the firms entry to the American market in a significant way. The isolate, which conforms to US Farm Bill standards, is expected to begin arriving in the current quarter to the supplier, with all product being shipped from Columbia.

The venture exchange has approved the company for the importation of up to US$3.0 million in hemp derived CBD isolate to the United States. Any further quantities will require addition venture approval.

PharmaCielo last traded at $3.54 on the TSX Venture.


Information for this briefing was found via Sedar and PharmaCielo Ltd. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Tudor Gold x American Creek: Consolidating A Massive Gold Project

Aura Minerals: The Era Dorada Underground PEA

Gold Is Now Smart Money’s End Game | Doug Casey

Recommended

Goliath Resources Expands 2025 Drill Program To 60,000 Metres

Emerita Resources Formally Appeals Administrative Ruling On Aznalcóllar Related To 2017 Complaint 

Related News

PharmaCielo Struggles To Complete Financing, Extends Closing To March

It appears that PharmaCielo (TSXV: PCLO) is having a difficult time raising funds for its...

Friday, February 4, 2022, 08:22:08 AM

Pharmacielo Latest Target of Hindenburg Research

Pharmacielo Ltd (TSXV: PCLO) is the latest target of short sellers Hindenburg Research, with Hindenburg...

Monday, March 2, 2020, 09:39:09 AM

PharmaCielo Third Quarter Revenues Crater 97.9%, CEO Forced Out

PharmaCielo Ltd (TSXV: PCLO) this morning filed its third quarter financial results, posting brutal revenues...

Monday, November 30, 2020, 08:34:11 AM

PharmaCielo Enters Supply Agreement With Xphyto Therapeutics

PharmaCieolo Ltd. (TSXV: PCLO) has announced a supply agreement with Xphyto Therapeutics Corp (CSE: XPHY)....

Monday, January 27, 2020, 11:04:28 AM

Drug Trade: The Three Basic Cannabis Health Company Archetypes

The popular belief that cannabis will work its way further into mainstream culture and further...

Saturday, December 21, 2019, 08:00:00 AM